All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Sosei Heptares Ltd. has signed up Glaxosmithkline plc to take on the orphan G protein-coupled (GPCR) target GPR35, in a deal worth a potential $481 million.
